

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00241)

**RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON AUGUST 7, 2026**

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”) is pleased to announce that, on August 7, 2026, the Company held its annual general meeting (the “**AGM**”) at which all the resolutions set out in the notice of annual general meeting dated July 6, 2026 (the “**Notice**”) were duly passed by the shareholders of the Company (the “**Shareholders**”) by way of poll.

References are made to (i) the Notice; and (ii) the circular of the Company dated July 6, 2026 (the “**Circular**”). Capitalized terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

RESULTS OF THE AGM

The Board is pleased to announce that at the AGM held at Qingfeng Pavilion, FlyZoo Hotel, 969 Wenyi West Road, Wuchang Subdistrict, Yuhang District, Hangzhou, China on Friday, August 7, 2026 at 11:00 a.m., all the resolutions set out in the Notice (the “**Resolutions**”) were duly passed by way of poll by the Shareholders. The poll results in respect of the Resolutions are as follows:

ORDINARY RESOLUTIONS		NUMBER OF SHARES VOTED (%)	
		FOR	AGAINST
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended March 31, 2026.	10,057,083,764 (99.98%)	2,422,500 (0.02%)

ORDINARY RESOLUTIONS		NUMBER OF SHARES VOTED (%)	
		FOR	AGAINST
2.	Subject to the special resolution no. 10 being duly passed and the Reduction of Share Premium (as hereinafter defined) becoming effective, to approve the Company's distribution out of its contributed surplus account of an amount of RMB960,000,000 (by way of declaring and paying a final dividend of RMB5.95 cents per share of the Company) in cash for the year ended March 31, 2026 to the Shareholders whose names appear on the Company's register of members at the close of business on August 13, 2026.	10,054,396,441 (99.95%)	4,911,823 (0.05%)
3.	Subject to the special resolution no. 10 being duly passed and the Reduction of Share Premium (as hereinafter defined) becoming effective, to approve the Company's distribution out of its contributed surplus account of an amount of RMB2,180,000,000 (by way of declaring and paying a special dividend of RMB13.52 cents per share of the Company) in cash for the year ended March 31, 2026 to the Shareholders whose names appear on the Company's register of members at the close of business on August 13, 2026.	10,053,796,441 (99.95%)	4,911,823 (0.05%)
4.	To re-elect the following retiring directors of the Company:		
	(a) Ms. Sheng Mengyue as an executive Director;	10,039,378,620 (99.81%)	19,329,644 (0.19%)
	(b) Ms. Huang Yi Fei (Vanessa) as an independent non-executive Director;	9,971,843,372 (99.14%)	86,864,892 (0.86%)
	(c) Dr. Shao Rong as an independent non-executive Director; and	9,967,283,419 (99.09%)	91,424,845 (0.91%)
	(d) Ms. Wu May Yihong as an independent non-executive Director.	9,949,697,701 (98.92%)	109,010,563 (1.08%)
5.	To authorize the Board to fix the Directors' remuneration.	9,970,057,851 (99.12%)	88,650,413 (0.88%)

ORDINARY RESOLUTIONS		NUMBER OF SHARES VOTED (%)	
		FOR	AGAINST
6.	To re-appoint Ernst & Young as the auditor of the Company and to authorize the Board to fix its remuneration.	9,892,504,107 (98.35%)	166,204,157 (1.65%)
7.	To grant a general mandate to the Directors to issue and allot shares.	9,317,924,351 (92.64%)	740,783,913 (7.36%)
8.	To grant a general mandate to the Directors to repurchase shares.	10,053,692,441 (99.95%)	5,015,823 (0.05%)
9.	To approve the addition of the aggregate amount of shares repurchased as mentioned in ordinary resolution no. 8 to the aggregate amount that may be issued and allotted pursuant to ordinary resolution no. 7.	9,431,909,767 (93.77%)	626,798,497 (6.23%)
SPECIAL RESOLUTIONS		NUMBER OF SHARES VOTED (%)	
		FOR	AGAINST
10.	To approve the reduction of share premium from RMB51,686,866,000 by RMB10,000,000,000 to RMB41,686,866,000 standing to the credit of the share premium account of the Company on the effective date (the “ Reduction of Share Premium ”) and the crediting of the amount to the contributed surplus account, to authorize the Directors to apply such amount as they consider appropriate, and to authorize any Director to give effect to the foregoing.	10,053,796,441 (99.95%)	4,911,823 (0.05%)
11.	To approve the proposed amendments to the bye-laws of the Company, details of which are set out in the section headed “APPENDIX II — PROPOSED AMENDMENTS TO THE BYE-LAWS” in the Circular.	10,053,798,691 (99.95%)	4,909,573 (0.05%)

Notes:

- (1) The full text of the Resolutions is set out in the Notice.
- (2) To the best knowledge, belief and information of the Directors, as at the date of the AGM:
 - (a) the total number of Shares in issue was 16,175,300,965;

- (b) the Trustee held in aggregate 12,492,872 Shares under the CP Trust Account and the NCP Trust Account under the 2014 Share Award Scheme and the 2024 Share Award Scheme, representing in aggregate 0.08% of the issued share capital of the Company. The Trustee is required to abstain, and has abstained, from voting on all of the Resolutions at the AGM;
 - (c) the total number of Shares entitling the Shareholders to attend and vote for or against the Resolutions at the AGM was 16,162,808,093;
 - (d) the total number of Shares entitling the Shareholders to attend and vote only against the Resolutions at the AGM was nil; and
 - (e) save as disclosed, there were no Shares entitling the holder to attend and abstain from voting in favour of the Resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), no Shareholders were required under the Listing Rules to abstain from voting on the Resolutions, and there were no Shareholders that had stated their intention in the Circular to vote against or abstain from voting in respect of any Resolutions proposed at the AGM.
- (3) The Directors that attended the AGM were Mr. Shen Difan, Ms. Sheng Mengyue, Ms. Huang Jiaojiao, Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong.
- (4) Tricor Investor Services Limited, the Company’s branch share registrar and transfer office in Hong Kong, was appointed as the scrutineer at the AGM for the purpose of vote-taking in respect of the Resolutions.

As more than 50% of the total votes were cast in favour of each of Resolutions no. 1 to no. 9, these Resolutions were duly passed as ordinary resolutions of the Company.

As more than 75% of the total votes were cast in favour of each of Resolutions no. 10 and no. 11, these Resolutions were duly passed as special resolutions of the Company.

By order of the Board of
Alibaba Health Information Technology Limited
Shen Difan
Chairman and Chief Executive Officer

Hong Kong, August 7, 2026

As at the date of this announcement, the Board comprises Mr. Shen Difan and Ms. Sheng Mengyue as the executive Directors; Ms. Huang Jiaojiao as the non-executive Director; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.